CC
PTGX icon

Checkpoint Capital’s Protagonist Therapeutics PTGX Stock Holding History

Checkpoint Capital’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-81,311
Closed -$4.49M – 11
2025
Q2 		$4.49M Sell
81,311
-93,873
-54% -$4.51M 2.09% 8
2025
Q1 		$8.47M Buy
+175,184
New +$7.34M 4.65% 6
2024
Q4 		– Sell
-240,000
Closed -$10.8M – 18
2024
Q3 		$10.8M Sell
240,000
-115,000
-32% -$4.65M 5.36% 7
2024
Q2 		$12.3M Buy
355,000
+74,699
+27% +$2.19M 7.42% 5
2024
Q1 		$8.11M Buy
280,301
+13,445
+5% +$366K 5.42% 7
2023
Q4 		$6.12M Buy
+266,856
New +$4.67M 3.71% 9

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Checkpoint Capital's PTGX Position: Q3 2025 in Review

Checkpoint Capital sold out of Protagonist Therapeutics (PTGX) in Q3 2025, closing a stake of 81,311 shares — an estimated $4.49M sold.

Checkpoint Capital first reported a position in PTGX in Q4 2023 and held it in 6 quarters. The position peaked at $12.3M in Q2 2024. 275 funds tracked by Wall St. Rank hold PTGX as of Q3 2025.

  • Checkpoint Capital reported no remaining Protagonist Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Checkpoint Capital sold 81,311 Protagonist Therapeutics shares in Q3 2025, an estimated $4.49M.
  • Checkpoint Capital first reported a position in Protagonist Therapeutics in Q4 2023 and held it in 6 quarters.
  • Checkpoint Capital's Protagonist Therapeutics position peaked at $12.3M in Q2 2024.
  • 275 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2025.

Based on Checkpoint Capital's 13F filing for Q3 2025, filed 14 Nov 2025.